Dual effect of quercetin on rat isolated portal vein smooth muscle contractility

Cardiovascular Journal of Africa

Volumn 21, Issue 3, 2010, Pages 132-136

  Chiwororo, Witness D H ^a   Ojewole, John A O ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

cAMP dependent protein kinases; Dual effects; Endothelium dependent relaxing factor; Prostacyclin; Quercetin; Rat isolated portal vein

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CALCIUM CHANNEL L TYPE; CYCLIC AMP; ENDOTHELIUM DERIVED RELAXING FACTOR; FLAVONOID; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; PRAZOSIN; QUERCETIN; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE INHIBITOR; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; INCUBATION TIME; MALE; NONHUMAN; PORTAL VEIN; RAT; SMOOTH MUSCLE CONTRACTILITY; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; IN VITRO STUDY; METABOLISM; PHYSIOLOGY; TIME; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION; WISTAR RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; EPOPROSTENOL; FEMALE; IN VITRO TECHNIQUES; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; PORTAL VEIN; PROTEIN KINASE INHIBITORS; QUERCETIN; RATS; RATS, WISTAR; TIME FACTORS; VASOCONSTRICTION; VASODILATION; VASODILATOR AGENTS;

EID: 77953295538     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Saponara S, Sgaragli G., Fusi F. Quercetin as a novel activator of L-type Ca2+ channels in rat tail artery smooth muscle cells. Br J Pharmacol 2002; 135: 1819-1827.
2. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Revista Neurol 1997; 153: 185-192. (Pubitemid 27262834)
3. Hertog MG., Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet 1993; 342: 1007-1011.
4. Hertog MG., Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Int Med 1995; 155: 381-386.
5. Renaud SC, Gueguen R, Schenker J, D'Houtaud A. Alcohol and mortality in middle-aged men from eastern France. Epidemiology 1998; 9: 184-188. (Pubitemid 28157617)
6. Renaud SC, Gueguen R, Siest G., Salamon R. Wine, beer, and mortality in middle-aged men from eastern France. Arch Int Med 1999; 159: 1865-1870.
7. Middleton E (jun), Kandaswami C, Theoharides CT. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000; 52: 673-751.
8. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol, 1996; 27: 363-366.
9. Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 1995; 33: 1061-1080.
10. Duarte J, Galisteo M, Ocete MA, Pérez-Vizcaíno F, Zarzuelo A, Tamargo J. Effects of chronic quercetin treatment on hepatic oxidative status of spontaneously hypertensive rats. Molec Cell Biochem 2001; 221: 155-160.
11. Duarte J, Pérez-Palencia R, Vargas F, Pérez-Vizcaíno F, Zarzuelo A, Tamargo J. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol 2001; 133:117-124. (Pubitemid 32500458)
12. Ferrell JE, Sing PDC, Loew G., King R, Mansour JM, Mansour TE. Structure-activity studies of flavonoids as inhibitors of cyclic AMP phosphodiesterase and relationship to quantum chemical indices. Molec Pharmacol 1979; 16: 556-568. (Pubitemid 10245880)
13. Landolfi R, Mower RL, Steiner M. Modification of platelet function and arachidonic acid metabolism by bioflavonoids: structure-activity relations. Biochem Pharmacol 1984; 33: 1525-1530.
14. Ortmann R, Nutto D, Waldmeyer J. Phloretin and related compounds inhibit agonist-stimulated cAMP accumulation in cultured cells of CNS origin. Biochem Pharmacol 1979; 28: 2357-2361.
15. Ruckstuhl M, Landry Y. Inhibition of lung cyclic AMP- and cyclic GMP-phosphodiesterase by flavonoids and other chromone-like compounds. Biochem Pharmacol 1981; 30: 697-702.
16. Whitten PL, Naftolin F. Dietary oestrogens: a biologically active background for oestrogen action. In: Hochberg RB, Naftolin F, eds. The New Biology of Steroid Hormones. New York: Raven Press, 1991: 155-167.
17. Lozoya X, Meckes M, Aboud-Zaid M, Tortoriello J, Nozolillo C, Amason JT. Quercetin glycosides in Psidium guajava L. leaves and determination of a spasmolytic principle. Arch Med Res 1994; 25:11-15. (Pubitemid 24138167)
18. Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M, Hidaka H. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine-threonine protein kinases. Bioch Pharmacol 1988; 37: 2987-2999.
19. Pérez-Vizcaíno F, Ibarra M, Cogolludo AL, Duarte J, Zaragozaírnaéz F, Moreno L, et al. Endothelium-independent vasodilator effects of the flavonoid quercetin and its methylated metabolites in rat conductance and resistance arteries. J Pharmacol Exp Therapeut 2002; 302(1): 66-72.
20. Rogers JC, Williams DL. Kaempferol inhibits myosin light chain kinase. Biochem Biophys Res Commun 1989; 164: 419-425. (Pubitemid 19269749)
21. Beretz A, Anton R, Stoclet J. Flavonoid compounds are potent inhibitors of cyclic AMP phosphodiesterase. Experientia 1978; 34: 1054-1055. (Pubitemid 8390309)
22. Beretz A, Stoclet J, Anton R. Inhibition of rat isolated aorta contraction by flavonoids. Possible correlation with cAMP-phosphodiesterase inhibition. Planta Medica 1980; 39: 236.
23. Petkov E, Uzunov P, Kostova I, Somleva T, Ognyanov I. Inhibition of rat heart phosphodiesterase by some rotenoids and isoflavonoids. Planta Medica 1983; 47: 237-239. (Pubitemid 13096867)
24. Duarte J, Pérez-Vizcaíno F, Jimenez J, Tamargo J, Zarzuelo A. Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships. Gen Pharmacol 1993; 24: 857-862.
25. Duarte J, Pérez-Vizcaíno F, Zarzuelo A, Jimenez J, Tamargo J. Vasodilator effects of quercetin on isolated rat vascular smooth muscle. Eur J Pharmacol 1993; 239: 1-7. (Pubitemid 23240133)
26. Chan ECH, Pannangpetch P, Woodman OL. Relaxation of flavones and flavonols in rat isolated thoracic aorta: mechanism of action and structure-activity relationships. J Cardiovasc Pharmacol 2000; 35: 326-333.
27. Herrera MD, Zarcuelo A, Jimdnez J, Marhuenda E, Duarte J. Effects of flavonoids on rat aortic smooth muscle contractility: structure-activity relationships. Gen Pharmacol 1996; 27(2): 273-277. (Pubitemid 26129187)
28. Ethics Committee. Guide to the Care and Use of Laboratory Animals in Research and Teaching. Durban: University of KwaZulu-Natal, 2009.
29. Revuelta MP, Cantabrana B, Hidalgo A. Depolarization-dependent effect of flavonoids in rat uterine smooth muscle contraction elicited by CaCI2. Gen Pharmacol 1997; 29(5): 847-857. (Pubitemid 27475177)
30. Navasa M, Bosch J, Rhodes J. Pharmacological agents and portal hypertension. In: Okuda K, Benhamou JP, eds. Portal Hypertension: Clinical and Physiological Aspects. Berlin: Springer Verlag, 1991: 35-49.
31. Ajay M, Achike FI, Mustafa AM, Mustafa MR. Effect of quercetin on altered vascular reactivity in aortae isolated from streptozotocin-induced diabetic rats. Diabetes Res Clin Prac 2006; 73: 1-7.
32. Rice-Evans A, Packer L. Flavonoids in Health and Disease. New York: Marcel Dekker Inc, 1998.